Chronic Pain Treatment With Cannabidiol in Kidney Transplant Patients in Uruguay
Abstract
Background Chronic pain is a major therapeutic problem in kidney transplant patients owing to nephrotoxicity associated with nonsteroidal antiiflammatory drugs. Benefits in chronic pain treatment with cannabidiol (CBD) have been reported. This study assesses the effect, safety, and possible drug interactions in kidney transplant patients treated with CBD for chronic pain.Methods We assessed patients who asked to receive CBD for pain treatment. Doses were increased from 50 to 150 mg twice a day for 3 weeks. Creatinine, blood count, liver function, liver enzymes, and drug levels were determined every 48 hours the first week and then once a week thereafter.Results We assessed 7 patients with a mean age of 64.5 years (range, 58-75 years). CBD initial dose was 100 mg/d, CBD dose reduction to 50 mg/d has been done on day 4 to patient 1 for persistent nausea. Tacrolimus dose reduction in patient 3 was undertaken on days 4, 7, and 21 owing to persisting elevated levels (even before CBD) and itching, and on day 21 in patient 5. Tacrolimus levels decreased in patient 2 but were normal in the control 1 week later. Patients on cyclosporine were stable. Adverse effects were nausea, dry mouth, dizziness, drowsiness, and intermittent episodes of heat. CBD dose decrease was required in 2 patients. Two patients had total pain improvement, 4 had a partial response in the first 15 days, and in 1 there was no change.Conclusions During this follow-up, CBD was well-tolerated, and there were no severe adverse effects. Plasma levels of tacrolimus were variable. Therefore, longer follow-up is required.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Although the five studies found improvements in nausea with cannabis use, other studies found nausea to be an adverse event associated with cannabis use among some participants.
“Although these five studies found improvements in nausea with cannabis use, other studies found nausea to be an adverse event associated with cannabis use among some participants.”
From Clinical Practice Guidelines for Cannabis and Cannabinoid-Based Medicines in the Management of Chronic Pain and Co-Occurring Conditions (2024) · cites this paper as [71]
Cites
Wolfe, R. A., Ashby, V. B., Milford, E. L., OJO, A. O., Ettenger, R. E., Agodoa, L. Y. C., Held, P. J., & Port, F. K. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912023412303 · Cited by 5,370 · see citing works
Pharmacokinetics and Pharmacodynamics of Cannabinoids
Grotenhermen, F. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342040-00003 · Cited by 1,514 · see citing works
Meier‐Kriesche, H., Schold, J. D., & Kaplan, B. E. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00515.x · Cited by 602 · see citing works
Acetaminophen-induced nephrotoxicity: Pathophysiology, clinical manifestations, and management
Mazer, M., & Perrone, J. (2008) · Journal of Medical Toxicology · doi:10.1007/bf03160941 · Cited by 399 · see citing works
Pertwee, R. G. (2012) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2011.0381 · Cited by 351 · see citing works
Stout, S. M., & Cimino, N. M. (2013) · Drug Metabolism Reviews · doi:10.3109/03602532.2013.849268 · Cited by 350 · see citing works
Jiang, R., Yamaori, S., Takeda, S., Yamamoto, I., & Watanabe, K. (2011) · Life Sciences · doi:10.1016/j.lfs.2011.05.018 · Cited by 322 · see citing works
Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside
Rahn, E. J., & Hohmann, A. G. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.08.002 · Cited by 305 · see citing works
Ujváry, I., & Hanuš, L. (2016) · Cannabis and Cannabinoid Research · doi:10.1089/can.2015.0012 · Cited by 302 · see citing works
CB2 Cannabinoid Receptors as a Therapeutic Target—What Does the Future Hold?
Dhopeshwarkar, A., & Mackie, K. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.094649 · Cited by 254 · see citing works
Drug-Induced Renal Failure: Update on New Medications and Unique Mechanisms of Nephrotoxicity
Perazella, M. A. (2003) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200306000-00006 · Cited by 225 · see citing works
Targeting CB2 receptors and the endocannabinoid system for the treatment of pain
Anand, P., Whiteside, G. T., Fowler, C. J., & Hohmann, A. G. (2008) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.12.003 · Cited by 217 · see citing works
Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis.
Goto, T., KINO, T., Hatanaka, H., Nishiyama, M., OKUHARA, M., KOHSAKA, M., Aoki, H., & Imanaka, H. (1987) · PubMed · Cited by 216 · see citing works
The Role of the Endocannabinoid System in Pain
Woodhams, S. G., Sagar, D. R., Burston, J. J., & Chapman, V. (2015) · Handbook of experimental pharmacology · doi:10.1007/978-3-662-46450-2_7 · Cited by 205 · see citing works
Neurologic complications after solid organ transplantation.
Marco, S., Cecilia, F., & Patrizia, B. (2009) · Transplant International · doi:10.1111/j.1432-2277.2008.00780.x · Cited by 191 · see citing works
Modulation of Peripheral Sensory Neurons by the Immune System: Implications for Pain Therapy
Stein, C., & Machelska, H. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003145 · Cited by 182 · see citing works
Bestard, O., Cruzado, J. M., Mestre, M., Caldés, A., Bas, J., Carrera, M., Torrás, J., Rama, I., Moreso, F., Serón, D., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.7.4901 · Cited by 161 · see citing works
Presence of FoxP3+ Regulatory T Cells Predicts Outcome of Subclinical Rejection of Renal Allografts
Bestard, O., Cruzado, J. M., Rama, I., Torrás, J., Accent], M. G. G., Serón, D., Moreso, F., Gil‐Vernet, S., & Accent, J. M. G. A. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007111174 · Cited by 159 · see citing works
Cannabidiol, a Major Phytocannabinoid, As a Potent Atypical Inhibitor for CYP2D6
Yamaori, S., Okamoto, Y., Yamamoto, I., & Watanabe, K. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.041384 · Cited by 151 · see citing works
Clinically Significant Drug Interactions with New Immunosuppressive Agents
Mignat, C. (1997) · Drug Safety · doi:10.2165/00002018-199716040-00004 · Cited by 133 · see citing works
Bestard, O., Nickel, P., Cruzado, J. M., Schoenemann, C., Boenisch, O., Sefrin, A., Grinyo, J. M., Volk, H., & Reinke, P. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007050539 · Cited by 132 · see citing works
Mortality in chronic kidney disease and renal replacement therapy: a population-based cohort study
Neovius, M., Jacobson, S. H., Eriksson, J. K., Elinder, C., & Hylander, B. (2014) · BMJ Open · doi:10.1136/bmjopen-2013-004251 · Cited by 131 · see citing works
Endocannabinoids: A unique opportunity to develop multitarget analgesics
Maione, S., Costa, B., & Marzo, V. D. (2013) · Pain · doi:10.1016/j.pain.2013.03.023 · Cited by 102 · see citing works
A preliminary investigation on the distribution of cannabinoids in man
Gronewold, A., & Skopp, G. (2011) · Forensic Science International · doi:10.1016/j.forsciint.2011.04.010 · Cited by 81 · see citing works
Bestard, O., Cuñetti, L., Cruzado, J. M., Lúcia, M., Valdez, R., Olek, S., Melilli, E., Torrás, J., Mast, R., Gomà, M., et al. (2011) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03633.x · Cited by 80 · see citing works
Self-citationDynamic changes to the endocannabinoid system in models of chronic pain
Sagar, D. R., Burston, J. J., Woodhams, S. G., & Chapman, V. (2012) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2011.0390 · Cited by 76 · see citing works
FK506 in Solid Organ Transplantation
Fung, J. J., & Starzl, T. E. (1995) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199512000-00008 · Cited by 56 · see citing works
Influence of interactions between immunosuppressive drugs on therapeutic drug monitoring.
Kuypers, D. R. J. (2008) · PubMed · Cited by 55 · see citing works
Hunt, C. A., Jones, R. T., Herning, R. I., & Bachman, J. (1981) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059266 · Cited by 50 · see citing works
Yates, M. L., & Barker, E. L. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.055251 · Cited by 50 · see citing works
Mitigating the Cardiovascular and Renal Effects of NSAIDs: Table 1
Curiel, R., & Katz, J. D. (2013) · Pain Medicine · doi:10.1111/pme.12275 · Cited by 42 · see citing works
Campistol, J. M., & Jm, G. (2001) · PubMed · Cited by 41 · see citing works
Flagged first, then by citations
1 of the 33 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action
Mlost, J., Bryk, M., & Starowicz, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228870 · Cited by 300 · see citing works
A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential
White, C. M. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1387 · Cited by 247 · see citing works
Sholler, D. J., Schoene, L., & Spindle, T. R. (2020) · Current Addiction Reports · doi:10.1007/s40429-020-00326-8 · Cited by 143 · see citing works
Cannabis, the Endocannabinoid System and Immunity—the Journey from the Bedside to the Bench and Back
Almogi‐Hazan, O., & Or, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124448 · Cited by 132 · see citing works
“showed pain improvement in six out of seven kidney transplant patients receiving CBD, but they did not examine the effect on organ rejection [128].”
BackgroundEvidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus
Leino, A. D., Emoto, C., Fukuda, T., Privitera, M., Vinks, A. A. T. M. M., & Alloway, R. R. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15398 · Cited by 117 · see citing works
Development of a Novel Nanoemulsion Formulation to Improve Intestinal Absorption of Cannabidiol
Nakano, Y., Tajima, M., Sugiyama, E., Sato, V. H., & Sato, H. (2019) · Medical Cannabis and Cannabinoids · doi:10.1159/000497361 · Cited by 108 · see citing works
Vela, J., Dreyer, L., Petersen, K. K., Arendt‐Nielsen, L., Duch, K. S., & Kristensen, S. (2021) · Pain · doi:10.1097/j.pain.0000000000002466 · Cited by 107 · see citing works
Use of cannabidiol (CBD) for the treatment of chronic pain
Urits, I., Gress, K. L., Charipova, K., Habib, K., Lee, D. M., Lee, C. S., Jung, J. W., Kassem, H., Cornett, E. M., Paladini, A., et al. (2020) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2020.06.004 · Cited by 104 · see citing works
Bell, A. D., MacCallum, C., Margolese, S., Walsh, Z., Wright, P., Daeninck, P. J., Mandarino, E., Lacasse, G., Kaur Deol, J., de Freitas, L., et al. (2024) · Cannabis & Cannabinoid Research · doi:10.1089/can.2021.0156 · Cited by 78 · see citing works
A Balanced Approach for Cannabidiol Use in Chronic Pain
Argueta, D. A., Ventura, C. M., Kiven, S. B., Sagi, V., & Gupta, K. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00561 · Cited by 78 · see citing works
“…cortex and striatum of rats exposed prenatally to either CBD or THC exhibited smaller binding affinities for their respective ligands and hypothalamic dopamine levels in mice have been observed to be greatly depleted in CBD-exposed males as well (Dalterio et al., 1984; Walters and Carr, 1988).”
BackgroundClinical Relevance of Drug Interactions with Cannabis: A Systematic Review
Lopera, V., Rodríguez, A., & Amariles, P. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11051154 · Cited by 66 · see citing works
Is cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms?
Crippa, J. A. S., Hallak, J. E. C., Zuardi, A. W., Guimarães, F. S., Tumas, V., & SANTOS, R. G. D. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-00982-6 · Cited by 66 · see citing works
Cannabidiol and brain function: current knowledge and future perspectives
Schouten, M., Dalle, S., Mantini, D., & Koppo, K. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1328885 · Cited by 61 · see citing works
“In a study involving seven kidney transplant patients with chronic pain, CBD treatment (100 – 300 mg/d for 3 weeks) resulted in total pain reduction in two patients and a partial reduction in four patients, while one patient did not perceive any change in symptoms at all (Cuñetti et al., 2018).”
BackgroundThe nephrologistʼs guide to cannabis and cannabinoids
Rein, J. L. (2020) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000590 · Cited by 52 · see citing works
Opportunities, Challenges and Pitfalls of Using Cannabidiol as an Adjuvant Drug in COVID-19
Malinowska, B., Baranowska‐Kuczko, M., Kicman, A., & Schlicker, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041986 · Cited by 50 · see citing works
Oral efficacy of Δ(9)-tetrahydrocannabinol and cannabidiol in a mouse neuropathic pain model
Mitchell, V. A., Harley, J. C., Casey, S. L., Vaughan, A. C., Winters, B. L., & Vaughan, C. W. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108529 · Cited by 48 · see citing works
Boehnke, K. F., Scott, J. R., Litinas, E., Sisley, S., Williams, D. A., & Clauw, D. J. (2019) · Journal of Pain · doi:10.1016/j.jpain.2019.09.006 · Cited by 47 · see citing works
Cannabidiol for the Treatment of Brain Disorders: Therapeutic Potential and Routes of Administration
Yau, G. T. Y., Tai, W., Arnold, J. C., Chan, H., & Kwok, P. C. L. (2023) · Pharmaceutical Research · doi:10.1007/s11095-023-03469-1 · Cited by 46 · see citing works
Nachnani, R., Knehans, A. C., Neighbors, J. D., Kocis, P. T., Lee, T., Tegeler, K., Trite, T., Raup‐Konsavage, W. M., & Vrana, K. E. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1282831 · Cited by 47 · see citing works
“Cuñetti and colleagues (Cuñetti et al., 2018) report the effects of 21 days of scaled CBD on chronic pain and serum tacrolimus levels in seven kidney transplant cases.”
BackgroundSamarehfekri, A., Dehghan, M., Arab, M., & Ebadzadeh, M. R. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/5095071 · Cited by 40 · see citing works
Cannabidiol (CBD): A Systematic Review of Clinical and Preclinical Evidence in the Treatment of Pain
Cásedas, G., de Yarza-Sancho, M., & López, V. (2024) · Pharmaceuticals · doi:10.3390/ph17111438 · Cited by 36 · see citing works
Evaluation of potential drug–drug interactions with medical cannabis
Ho, J. J. Y., Goh, C., Leong, C. S. A., Ng, K. Y., & Bakhtiar, A. (2024) · Clinical and Translational Science · doi:10.1111/cts.13812 · Cited by 32 · see citing works
Cannabidiol (CBD) Use by Older Adults for Acute and Chronic Pain
Porter, B., Marie, B. S., Milavetz, G., & Herr, K. (2021) · Journal of Gerontological Nursing · doi:10.3928/00989134-20210610-02 · Cited by 33 · see citing works
Effectiveness of Cannabidiol to Manage Chronic Pain: A Systematic Review
Mohammed, S. Y. M., Leis, K., Mercado, R. E., Castillo, M. M. S., Miranda, K. J., & Carandang, R. R. (2023) · Pain Management Nursing · doi:10.1016/j.pmn.2023.10.002 · Cited by 27 · see citing works
Cannabidiol drug interaction considerations for prescribers and pharmacists
Graham, M., Martin, J. H., Lucas, C. J., Murnion, B. P., & Schneider, J. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2142114 · Cited by 26 · see citing works
“There have been case reports and/or series where altered tacrolimus concentrations have been observed with concurrent use of cannabidiol only or predominant products [72,73].”
BackgroundVerma, R., Hoda, F., Arshad, M., Iqubal, A., Siddiqui, A. N., Khan, M. A., Haque, S. E., Akhtar, M., & Najmi, A. K. (2021) · Medical Cannabis and Cannabinoids · doi:10.1159/000515042 · Cited by 26 · see citing works
Sexton, M. (2020) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2020.0144 · Cited by 24 · see citing works
Cannabidiol in Foods and Food Supplements: Evaluation of Health Risks and Health Claims
Engeli, B. E., Lachenmeier, D. W., Diel, P. R., Guth, S., Villar-Fernandez, M., Roth, A., Lampen, A., Cartus, A. T., Wätjen, W., Hengstler, J. G., et al. (2025) · Nutrients · doi:10.3390/nu17030489 · Cited by 22 · see citing works
Pisani, S., McGoohan, K., Velayudhan, L., & Bhattacharyya, S. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00882-2 · Cited by 22 · see citing works
Adjunctive Management of Opioid Withdrawal with the Nonopioid Medication Cannabidiol
Kudrich, C., Hurd, Y. L., Salsitz, E. A., & Wang, A. (2021) · Cannabis and Cannabinoid Research · doi:10.1089/can.2021.0089 · Cited by 21 · see citing works
“62 In an audit of 400 patients with chronic pain, a self-titrated dose of prescribed CBD decreased both pain and anxiety.”
Sideris, A., & Doan, L. (2023) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000006584 · Cited by 20 · see citing works
Chronic Pain and Cannabidiol in Animal Models: Behavioral Pharmacology and Future Perspectives
Silva-Cardoso, G. K., & Leite‐Panissi, C. R. A. (2022) · Cannabis and Cannabinoid Research · doi:10.1089/can.2022.0096 · Cited by 19 · see citing works
Amann, L., Kruse, E., Lazard, A. J., Reboussin, B. A., Wagoner, K. G., & Romero-Sandoval, E. A. (2022) · Journal of Pain Research · doi:10.2147/jpr.s384996 · Cited by 19 · see citing works
Medicinal applications of cannabis/cannabinoids
Braithwaite, I. E., Bhagavan, C., Doppen, M., Kung, S. M., Oldfield, K., & Newton‐Howes, G. (2020) · Current Opinion in Psychology · doi:10.1016/j.copsyc.2020.06.002 · Cited by 19 · see citing works
Renal impairment and analgesia: From effectiveness to adverse effects
Alizadeh, R. F., & fard, Z. A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28506 · Cited by 18 · see citing works
“It is also well‐tolerated, effective to treat chronic pain, and presented fewer severe adverse effects in kidney transplant patients (Cuñetti et al., 2018).”
BackgroundBioactive Chemical Composition of Cannabis Extracts and Cannabinoid Receptors
Yang, Y., Vyawahare, R., Lewis‐Bakker, M. M., Clarke, H. A., Wong, A. H. C., & Kotra, L. P. (2020) · Molecules · doi:10.3390/molecules25153466 · Cited by 18 · see citing works
Omotayo, O. P., Lemmer, Y., & Mason, S. (2024) · Journal of Cannabis Research · doi:10.1186/s42238-024-00222-2 · Cited by 18 · see citing works
A Phase I Trial of the Pharmacokinetic Interaction Between Cannabidiol and Tacrolimus
So, G. C., Lu, J. B. L., 小山, 幸., Cheng, Y., Gisch, D. L., McClara, K., Dexter, P. R., Sharfuddin, A., Etkins, J., Tillman, E. M., et al. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3504 · Cited by 15 · see citing works
Johnson, D., Santos, E. R., Kim, K., Ponzini, M., McLennan, Y. A., Schneider, A., Tassone, F., & Hagerman, R. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.762915 · Cited by 13 · see citing works
“A controlled trial examined pain in patients with multiple sclerosis, spinal cord, and other neurological conditions found pain control improved with CBD (78) in addition to two other studies that found pain relief (79, 80).”
ResultSeifalian, A., Kenyon, J., & Khullar, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232416201 · Cited by 14 · see citing works
Caicedo, D. A., Pérez‐Mañá, C., Farré, M., & Papaseit, E. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17030319 · Cited by 13 · see citing works
Melaragno, J. I., Bowman, L. J., Park, J. M., Lourenço, L. M., Doligalski, C. T., Brady, B. L., Descourouez, J. L., Chandran, M. M., Nickels, M. W., & Page, R. L., II (2020) · Transplantation · doi:10.1097/tp.0000000000003309 · Cited by 13 · see citing works
“A retrospective review of 7 RTRs treated with CBD for pain documented minimal adverse effects and variable efficacy (pain response: 2 complete, 4 partial, 1 no change).(9) Two patients required tacrolimus dose reduction, 1 on multiple occasions owing to persistently high levels.”
BackgroundThe growing dilemma of legalized cannabis and heart transplantation
Olt, C. K., Faulkenberg, K. D., & Hsich, E. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.03.024 · Cited by 10 · see citing works
Natural Cannabinoids as Templates for Sleep Disturbances Treatments
Murillo‐Rodríguez, E., Machado, S. E. D. C., Imperatori, C., Yamamoto, T., & Budde, H. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-61663-2_9 · Cited by 8 · see citing works
Autophagy: An Emerging Target for Developing Effective Analgesics
Manivasakam, P., Ravi, A., Ramesh, J., Bhuvarahamurthy, D., Kasirajan, K., Singaravel, V., Venugopal, B., & Fliri, A. F. (2023) · ACS Omega · doi:10.1021/acsomega.2c06949 · Cited by 8 · see citing works
Drug-Drug Interaction Between Cannabidiol, Cyclosporine, and Mycophenolate Mofetil: A Case Report
Cuñetti, L., Oricchio, F., Vázquez, M., Peyraube, R., Manzo, L. L., Nalerio, C., Curi, L., & Maldonado, C. (2024) · Transplantation Proceedings · doi:10.1016/j.transproceed.2023.11.013 · Cited by 7 · see citing works
Self-citationFleege, N. M. G., Miller, E. A., Kidwell, K., Zacharias, Z. R., Houtman, J. C. D., Scheu, K., Kemmer, K. A., Boehnke, K. F., & Henry, N. L. (2025) · Cancer Medicine · doi:10.1002/cam4.71117 · Cited by 6 · see citing works
Senderovich, H., Wagman, H., Zhang, D., Vinoraj, D., & Waicus, S. (2021) · Gerontology · doi:10.1159/000518269 · Cited by 6 · see citing works
Rakha, A., Rasheed, H., Altemimi, A. B., Tul‐Muntaha, S., Fatima, I., Butt, M. S., Hussain, S., Bhat, Z. F., Khaneghah, A. M., & Aadil, R. M. (2024) · Food Bioscience · doi:10.1016/j.fbio.2024.104195 · Cited by 6 · see citing works
“Over-the-counter” cannabidiol (CBD) sold in the community pharmacy setting in Colorado
Shea, L. A., Leeds, M., Bui, D., Mujica, M., Poupard, M., Rodriguez, R., Matura, J. M., Carnazzo, A., & Spence, A. L. (2020) · Drugs & Therapy Perspectives · doi:10.1007/s40267-020-00781-3 · Cited by 6 · see citing works
Inhibition of Tacrolimus Metabolism by Cannabidiol and Its Metabolites In Vitro
So, G. C., Lu, J. B. L., Cheng, Y., Gisch, D. L., 小山, 幸., Ferreira, R. M., Beamon, T. R., Desta, Z., & Eadon, M. T. (2025) · Clinical and Translational Science · doi:10.1111/cts.70152 · Cited by 5 · see citing works
CBD’s potential impact on Parkinson’s disease: An updated overview
Ghachi, H. E., Soulimani, R., Gamrani, H., & Kissani, N. (2024) · Open Medicine · doi:10.1515/med-2024-1075 · Cited by 6 · see citing works
“CBD has been shown to help with pain alleviation in several pre-clinical studies [96 – 98]; however, recent clinical trials evaluating the e ffi cacy of CBD alone in other forms of pain are reporting heterogeneous results [99 – 102], with the lack of those focusing on Parkinson-related forms of pain.”
ResultDing, Y., Wang, J., Kumar, V., Ciaccio, J. A., Dakhel, S., Tan, C. S., Kim, J., Lee, S., Katz-Lichtenstein, H., Youss, Z. B., et al. (2022) · International Journal of Innovative Research in Medical Science · doi:10.23958/ijirms/vol07-i06/1418 · Cited by 4 · see citing works
Tailored Iron Oxide Nanoparticles as Potential Cannabinoid Carriers for Anti-Cancer Treatment
Taudul, J., Celej, J., Żelechowska-Matysiak, K., Kępińska, D., Majkowska‐Pilip, A., Strawski, M., Krysiński, P., & Nieciecka, D. (2025) · Biomolecules · doi:10.3390/biom15020230 · Cited by 4 · see citing works
Hill, K. P., & Abrams, D. I. (2021) · Journal of Cannabis Research · doi:10.1186/s42238-021-00074-0 · Cited by 4 · see citing works
Biabani, F., Rahmani, A., Mahmudirad, G., Hassankhani, H., & Azadi, A. (2023) · Peritoneal Dialysis International · doi:10.1177/08968608221146865 · Cited by 4 · see citing works
Human Data on Pharmacokinetic Interactions of Cannabinoids: A Narrative Review
Maldonado, C., Peyraube, R., Fagiolino, P. L., Oricchio, F., Cuñetti, L., & Vázquez, M. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128288510240113170116 · Cited by 4 · see citing works
Self-citationCannabidiol: Knowledge, Beliefs, and Experiences of Patients With Cancer
Butler, T., Hande, K. A., Ryan, M., Chandrasekhar, R., McDowell, M. R., Cones, B., Jackson, H., Cortez, M., & Murphy, B. A. (2021) · Clinical journal of oncology nursing · doi:10.1188/21.cjon.405-412 · Cited by 3 · see citing works
Zhou, F. Y., Costa, A. F., & McLeod, M. (2021) · Canadian Liver Journal · doi:10.3138/canlivj-2021-0017 · Cited by 3 · see citing works
Employing Aeroponic Systems for the Clonal Propagation of Cannabis
Regas, T., Han, J.-H., Pauli, C. S., & Park, S. (2021) · Journal of Visualized Experiments · doi:10.3791/63117 · Cited by 3 · see citing works
Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review
Christo, P. J., Vortsman, E., Gharibo, C. G., LeQuang, J. A., & Pergolizzi, J. V. (2025) · Cureus · doi:10.7759/cureus.81577 · Cited by 3 · see citing works
The Role of Cannabidiol in Palliative Care #370
Christensen, A. R., & Pruskowski, J. A. (2019) · Journal of Palliative Medicine · doi:10.1089/jpm.2018.0670 · Cited by 3 · see citing works
O potencial terapêutico e farmacológico do canabidiol
da Silva, L. M. G., de Alencar, R. A., & Júnior, A. L. G. (2020) · Research Society and Development · doi:10.33448/rsd-v9i11.9686 · Cited by 3 · see citing works
Hulland, O., & Oswald, J. C. (2021) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2020.12.005 · Cited by 3 · see citing works
A UTILIZAÇÃO MEDICINAL DO CANABIDIOL COMO RECURSO TERAPÊUTICO: REVISÃO BIBLIOGRÁFICA
Alves, F. E. F. (2020) · Revista Interfaces Saúde Humanas e Tecnologia · doi:10.16891/2317-434x.v8.e2.a2020.pp581-590 · Cited by 3 · see citing works
Sokuma, A., Chatsungnoen, T., Susawaengsup, C., Tongkoom, K., & Bhuyar, P. (2026) · Molecular Biotechnology · doi:10.1007/s12033-026-01559-0 · Cited by 2 · see citing works
“According to Cuñetti et al. [115], in a study with seven kidney transplant patients who had chronic pain, two patients experienced complete pain relief and four experienced partial pain relief after taking 100 to 300 mg/d for three weeks of CBD treatment.”
AVALIAÇÃO DO TRATAMENTO DA FIBROMIALGIA: A TERAPIA COM CANABINOIDES
Lucena, L. R. T., Timoteo, P. A. D., & de Sousa, M. N. A. (2022) · Revista Contemporânea · doi:10.56083/rcv2n3-006 · Cited by 2 · see citing works
Villalobos-González, C. E., Gómez‐Carmona, C. D., Sánchez‐Ureña, B., Azofeifa-Mora, C., & Rojas‐Valverde, D. (2024) · Preprints.org · doi:10.20944/preprints202405.0517.v1 · Cited by 1 · see citing works
Chou, R., Wagner, J., Ahmed, A. Y., Morasco, B. J., Kansagara, D. L., Selph, S., Holmes, R. S., & Fu, R. (2022) · doi:10.23970/ahrqepccannabissurveillance4 · Cited by 1 · see citing works
Charrette, A., Akingbasote, J. A., Guthrie, N., & Hilmas, C. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821038-3.00039-2 · Cited by 1 · see citing works
Rodríguez‐Ramírez, S., Tang, E., Li, Y., Famure, O., Mucsi, I., & Kim, S. J. (2024) · Clinical Transplantation · doi:10.1111/ctr.15264 · Cited by 1 · see citing works
“36 It is estimated that more than 60% of cannabis products are mislabeled with respect to their actual CBD content.”
BackgroundMcDonagh, M. S., Wagner, J., Ahmed, A. Y., Morasco, B. J., Kansagara, D. L., & Chou, R. (2021) · doi:10.23970/ahrqepccerplantpain3 · Cited by 1 · see citing works
Pain in psoriatic arthritis and hand osteoarthritis
Vela, J. (2021) · doi:10.54337/aau460188407 · Cited by 1 · see citing works
Chou, R., Wagner, J., Ahmed, A. Y., Morasco, B. J., Kansagara, D. L., & Selph, S. (2022) · doi:10.23970/ahrqepccannabissurveillance3 · Cited by 1 · see citing works
Advances in Pharmacological Research of Cannabidiol
韩, 莎. (2019) · Pharmacy Information · doi:10.12677/pi.2019.83006
Taylor, C. F. C., & Birch, B. R. (2021) · Journal of Nephrological Science · doi:10.29245/2767-5149/2021/1.1110
Over-The-Counter Cannabidiol (CBD)
Shea, L. A. (2022) · Springer eBooks · doi:10.1007/978-3-030-67928-6_75-1
Pearlson, G. D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818174-4.00005-7
(2018) · Reactions Weekly · doi:10.1007/s40278-018-45329-6
McDonagh, M. S., Wagner, J., Ahmed, A. Y., Morasco, B. J., Kansagara, D. L., & Chou, R. (2022) · doi:10.23970/ahrqepccannabissurveillance2
Over-the-Counter Cannabidiol (CBD)
Shea, L. A. (2022) · Springer eBooks · doi:10.1007/978-3-030-92392-1_75
Cannabidiol (CBD) for relief from pain, anxiety, and epilepsy: A review
Özenver, N., & Agrawal, D. C. (2022) · International Journal of Applied Science and Engineering · doi:10.6703/ijase.202212_19(4).006
“No approved pharmaceutical medicine is available containing CBD alone (Cuñetti et al., 2018; Argueta et al., 2020; Verrico et al., 2020; FDA, 2022).”
BackgroundSystematic Review on Acute Treatments for Episodic Migraine: Surveillance Report 1
Singh, R. B. H., VanderPluym, J. H., Hasan, B., Farah, M. H., Viola, K. E., Saadi, S. M., Shah, S. H., Nayfeh, T., Prokop, L. J., Murad, M., et al. (2022) · doi:10.23970/ahrqepcmigrainesurveillance1
USO DA CANNABIS MEDICINAL PARA O TRATAMENTO DA DOR CRÔNICA: UMA REVISÃO INTEGRATIVA
da Silva, L. M. S. M., de Souza, N. G., do Carmo, R. O., Monari, G. M. G., & Buchaim, D. V. (2024) · Revista Omnia Saúde · doi:10.69719/ros.v7iesp..800
O papel dos canabinóides na modulação da inflamação e da dor crônica
Cardoso, V. K. L., Laborda, A. B., Gomes, C. C., BITENCOURT, D. B. F., de Souza, E. H. L., Mavignier, G. C. L. C., de Oliveira, G. S., Bessa, L. C. R., Zeni, M. E. F., Castro, R. A. B., et al. (2025) · Cuadernos de Educación y Desarrollo · doi:10.55905/cuadv17n1-078
When your patient asks about cannabidiol
Kudrich, C., & Wiggin, C. (2025) · Clinical Phytoscience · doi:10.1186/s40816-025-00402-4
“Oral doses of CBD have also been shown to be beneficial for chronic pain in kidney transplant patients when given a titrated dose of 50 to 150 mg twice daily over three weeks [29].”
Lisano, J. K., Rosa, L., Skrzynski, C. J., Bryan, A. D., & Bidwell, L. C. (2026) · Biomedicines · doi:10.3390/biomedicines14071642
“However, other clinical data utilizing doses of CBD ranging from 100 to 300 mg/day for up to 13 weeks did report significantly lower pain relative to placebo [46,47].”
O’Brien, K., Beilby, J., Lynskey, M. T., Barnes, M., Schlag, A. K., & Nutt, D. J. (2026) · Drug Science Policy and Law · doi:10.1177/20503245261488438
- Authors
- Cuñetti, L., Manzo, L., Peyraube, R., Arnaiz, J., Curi, L., & Orihuela, S.
- Affiliations
- Hospital Italiano de Montevideo (UY)
- Corresponding author
- Cuñetti, L.
- Venue
- Transplantation Proceedings
- Publisher
- Elsevier BV
- Published
- 2018-03
- Volume
- 50
- Issue
- 2
- Pages
- 461-464
- ISSN
- 0041-1345 (ISSN-L)
- OpenAlex
- W2790861309
- Cited by
- 90
- References
- 33
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 13 · 2023: 6 · 2022: 16 · 2021: 20 · 2020: 15 · 2019: 8 · 2018: 1
- FWCI
- 7.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Transplantation Proceedings (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- cannabidiol, chronic pain, kidney transplant recipients, tacrolimus, cyclosporine, drug interactions, immunosuppressive therapy, adverse effects, nausea, nephrotoxicity, nonsteroidal anti-inflammatory drugs, tolerability
- MeSH terms
- Aged, Cannabidiol, Female, Humans, Male, Middle Aged, Uruguay, Kidney Transplantation, Tacrolimus, Cyclosporine, Treatment Outcome, Chronic Pain, Pain Management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
